Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections

Next Previous
X
Search
Trial Profile

A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exeporfinium chloride (Primary)
  • Indications Postoperative infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Acronyms Landmark
  • Sponsors Destiny Pharma

    • Most Recent Events

    • 21 Aug 2024 According to a Destiny Pharma media release, clinical data from its Phase 2b clinical trial on XF-73 nasal administered to cardiac surgery patients has been accepted for an oral presentation at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) conference, the leading European conference on infectious disease in Porto, Portugal, entitled meeting the challenge of antimicrobial resistance, 17-20 September 2024.
    • 20 Sep 2023 According to a Destiny Pharma media release, data from this study were published in the leading US peer reviewed journal, Infection Control & Hospital Epidemiology
    • 09 Jul 2021 According to a Destiny Pharma media release, data from this trial will be presented at 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top